PACLITAXEL | N216338 | TEVA PHARMACEUTICALS INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | National Cancer Institute (NCI) | 117 | 2020-07-13 → 2026-12-31 | |
| Phase 2 | Active | ECOG-ACRIN Cancer Research Group | 249 | 2019-08-09 → 2027-03-31 | |
| Phase 2 | Active | AstraZeneca | 162 | 2010-02-04 → 2026-12-31 | |
| Phase 1 | Active | M.D. Anderson Cancer Center | 278 | 2010-08-19 → 2026-04-30 | |
| Phase 3 | Active | NRG Oncology | 450 | 2019-09-20 → 2028-02-01 | |
| Phase 1 | Active | AbbVie | 150 | 2019-05-21 → 2026-03 | |
| Phase 3 | Active | AstraZeneca | 805 | 2020-05-05 → 2027-04-01 | |
| Phase 1 | Active | Amgen | 610 | 2019-12-17 → 2027-12-05 | |
| Phase 2 | Active | Thomas Hatschek | 181 | 2015-02 → 2031-12-31 | |
| Phase 1/2 | Active | University Health Network, Toronto | 30 | 2016-07 → 2026-12 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$584.83
Highest Price
$1003.02
FSS NDCs
1
Big4 NDCs
1
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 00480-3290-01PACLITAXEL PROTEIN-BOUND 100MG/VIL INJ | $1003.02 | FSS | Teva Pharmaceuticals USA, Inc. | 04/30/2026 |
| 00480-3290-01PACLITAXEL PROTEIN-BOUND 100MG/VIL INJ | $584.83 | Big4 | Teva Pharmaceuticals USA, Inc. | 04/30/2026 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
18 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Nov 24, 2023 | SUPPL -1 | View Letter (PDF) |
| May 12, 2023 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.